Fred Alger Management
TRDA icon

Fred Alger Management’s Entrada Therapeutics TRDA Stock Holding History

Fred Alger Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17,955
Closed -$283K – 567
2022
Q3 		$283K Buy
+17,955
New +$228K ﹤0.01% 422

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Fred Alger Management's TRDA Position: Q4 2022 in Review

Fred Alger Management sold out of Entrada Therapeutics (TRDA) in Q4 2022, closing a stake of 17,955 shares — an estimated $283K sold.

Fred Alger Management first reported a position in TRDA in Q3 2022 and held it in 1 quarter. The position peaked at $283K in Q3 2022. 47 funds tracked by Wall St. Rank hold TRDA as of Q4 2022.

  • Fred Alger Management reported no remaining Entrada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Fred Alger Management sold 17,955 Entrada Therapeutics shares in Q4 2022, an estimated $283K.
  • Fred Alger Management first reported a position in Entrada Therapeutics in Q3 2022 and held it in 1 quarter.
  • Fred Alger Management's Entrada Therapeutics position peaked at $283K in Q3 2022.
  • 47 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q4 2022.

Based on Fred Alger Management's 13F filing for Q4 2022, filed 14 Feb 2023.